Reduced Antiviral Seropositivity among Patients with Inflammatory Bowel Disease Treated with Immunosuppressive Agents
Hisashi Shiga,Takahiro Takahashi,Manabu Shiraki,Yasuhiro Kojima,Tsuyotoshi Tsuji,Sho Takagi,Keiichiro Hiramoto,Naonobu Yokoyama,Mikako Sugimura,Masahiro Iwabuchi,Katsuya Endo,Motoyuki Onodera,Yuichirou Sato,Yosuke Shimodaira,Eiki Nomura,Tatsuya Kikuchi,Hirofumi Chiba,Shinya Oomori,Hisaaki Kudo,Kazuki Kumada,Satoshi Nagaie,Soichi Ogishima,Fuji Nagami,Yusuke Shimoyama,Rintaro Moroi,Masatake Kuroha,Yoichi Kakuta,Takashi Ishige,Yoshitaka Kinouchi,Atsushi Masamune
DOI: https://doi.org/10.1080/00365521.2022.2132831
2022-01-01
Scandinavian Journal of Gastroenterology
Abstract:Background Although live-attenuated vaccines are contraindicated under immunosuppression, the immune status of patients with inflammatory bowel disease (IBD) has not been fully assessed prior to immunosuppressive therapy. Aims To investigate antiviral serostatus against viruses requiring live vaccines for prevention in IBD patients undergoing immunosuppressive therapy. Methods This multicenter study included IBD patients who were aged <40 years and were treated with thiopurine monotherapy, molecular-targeted monotherapy, or combination therapy. Gender- and age-matched healthy subjects (HS) living in the same areas were included as control group. Antibody titers against measles, rubella, mumps, and varicella were measured by enzyme-linked immunosorbent assays. Results A total of 437 IBD patients (163 ulcerative colitis [UC] and 274 Crohn's disease [CD]) and 225 HS were included in the final analysis. Compared with HS, IBD patients had lower seropositivity rates for measles (IBD vs. HS = 83.91% vs. 85.33%), rubella (77.55% vs. 84.89%), mumps (37.50% vs. 37.78%), and varicella (91.26% vs. 96.44%). Gender- and age-adjusted seropositivity rates were lower in UC patients than in both CD patients and HS for measles (UC, CD, and HS = 81.60%, 85.29%, and 85.33%), rubella (76.40%, 78.23%, and 84.89%), mumps (27.16%, 43.70%, and 37.78%), and varicella (90.80%, 91.54%, and 96.44%); the difference was significant for all viruses except measles. Divided by the degree of immunosuppression, there were no significant differences in seropositivity rates among IBD patients. Conclusions IBD patients, especially those with UC, exhibit reduced seropositivity rates and may benefit from screening prior to the initiation of immunosuppressive therapy.